



(51) International Patent Classification:

A61K 38/19 (2006.01) *A61P 7/06* (2006.01)
A61K 31/22 (2006.01) *A61P 7/00* (2006.01)
A61K 31/235 (2006.01)

(21) International Application Number:

PCT/US2015/058732

(22) International Filing Date:

3 November 2015 (03.11.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/074,133 3 November 2014 (03.11.2014) US

(71) Applicant: **HYGEIA TECHNOLOGY INC.** [CA/CA];
 3033-8700 Mckim Way, Richmond, British Columbia
 V6X 4A5 (CA).

(72) Inventor; and

(71) Applicant (for *QA* only): **HAN, Zheng Tao** [US/US];
 1080 Patterson St., Apt. 903, Eugene, Oregon 97401 (US).

(74) Agents: **PHAN, Tu A.** et al.; Sughrue Mion, PLLC, 2100
 Pennsylvania Ave., N.W., Suite 800, Washington, District
 of Columbia 20037-3213 (US).


(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PHORBOL ESTER COMPOSITIONS AND METHODS FOR TREATING OR REDUCING THE DURATION OF
 CYTOPENIA

FIGURE 2



(57) Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and/or anemia.



Published:

— *with international search report (Art. 21(3))*